Epirubicin Enhances the Anti-Cancer Effects of Radioactive

Epirubicin JAK/STAT1 pathway anti-cancer effect hepatocellular carcinoma radioactive 125I seeds

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 13 01 2022
accepted: 20 04 2022
entrez: 13 6 2022
pubmed: 14 6 2022
medline: 14 6 2022
Statut: epublish

Résumé

The application and promotion of

Identifiants

pubmed: 35692770
doi: 10.3389/fonc.2022.854023
pmc: PMC9184686
doi:

Types de publication

Journal Article

Langues

eng

Pagination

854023

Informations de copyright

Copyright © 2022 Guo, Sun, Wang, Wang, Wang, Li and Li.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancer Lett. 2012 Mar 28;316(2):211-8
pubmed: 22075380
Biomed Res Int. 2016;2016:3048261
pubmed: 27999793
Mater Sci Eng C Mater Biol Appl. 2021 Oct;129:112390
pubmed: 34579909
Cancer Sci. 2020 Feb;111(2):621-636
pubmed: 31777993
Ther Adv Med Oncol. 2020 May 08;12:1758835920917558
pubmed: 32426049
Crit Rev Oncol Hematol. 2016 Jun;102:82-8
pubmed: 27083592
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Med Sci. 2020 Feb 18;17(5):609-619
pubmed: 32210710
Int J Clin Exp Pathol. 2018 Mar 01;11(3):1265-1272
pubmed: 31938221
Semin Cancer Biol. 2020 Feb;60:41-56
pubmed: 31605750
Int J Gynecol Cancer. 2018 Mar;28(3):459-465
pubmed: 29303938
J Mol Biol. 2020 Nov 6;432(22):5902-5919
pubmed: 32950480
Technol Cancer Res Treat. 2017 Dec;16(6):1083-1091
pubmed: 29332456
J Cancer Res Ther. 2018;14(7):1476-1481
pubmed: 30589026
Cell Death Dis. 2019 Oct 3;10(10):744
pubmed: 31582720
Front Oncol. 2021 Apr 21;11:582511
pubmed: 33968713
Int J Cancer. 2020 Mar 15;146(6):1717-1729
pubmed: 31709529
J Gastroenterol. 2018 Feb;53(2):281-290
pubmed: 28766016
Front Cell Dev Biol. 2021 Mar 23;9:636595
pubmed: 33834023
Eur J Cancer. 2021 Nov;157:373-382
pubmed: 34563992
Helicobacter. 2018 Sep;23 Suppl 1:e12518
pubmed: 30203589
BMC Cancer. 2016 Mar 07;16:193
pubmed: 26951097
Cancer Commun (Lond). 2019 Apr 29;39(1):22
pubmed: 31030667
PLoS One. 2013;8(2):e57397
pubmed: 23468980
Theranostics. 2021 Jan 1;11(3):1473-1492
pubmed: 33391546
Int J Urol. 2019 Feb;26(2):278-283
pubmed: 30515888
J Control Release. 2018 Dec 28;292:130-140
pubmed: 30391405
Onco Targets Ther. 2021 Jan 12;14:289-300
pubmed: 33469307
Cancer Biomark. 2022;34(1):95-103
pubmed: 34657877

Auteurs

Lei Guo (L)

Department of Vascular Anomalies and Interventional Radiology, Qilu Children's Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Jinan, China.
Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan, China.

Jiali Sun (J)

Department of Vascular Anomalies and Interventional Radiology, Qilu Children's Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Jinan, China.

Changjun Wang (C)

Department of Interventional Radiology, Jiyang People's Hospital of Jinan, Jinan, China.

Yang Wang (Y)

Department of Interventional Medicine, The Second Hospital, Cheello College of Medicine, Shandong University, Jinan, China.
Institute of Interventional Oncology, Shandong University, Jinan, China.

Ya Wang (Y)

Department of Vascular Anomalies and Interventional Radiology, Qilu Children's Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Jinan, China.

Dong Li (D)

Department of Interventional Medicine, The Second Hospital, Cheello College of Medicine, Shandong University, Jinan, China.
Institute of Interventional Oncology, Shandong University, Jinan, China.

Yuliang Li (Y)

Department of Interventional Medicine, The Second Hospital, Cheello College of Medicine, Shandong University, Jinan, China.
Institute of Interventional Oncology, Shandong University, Jinan, China.

Classifications MeSH